Epistem and Rottapharm Announce Positive Results
News Sep 10, 2008
CR 3294 is an inhibitor of pro-inflammatory gene expression involved in the pathogenesis of acute and chronic inflammatory events, endowed with potent Reactive Oxygen Species (ROS)-generation preventing effects, and with immunosuppressive and wound-healing properties.
Rottapharm is developing CR 3294 for chemotherapy induced diarrhoea, mucositis, and inflammatory bowel disease. At present there are no approved oncology supportive care drugs to reduce the severity of intestinal mucositis, which is typically associated with cancer therapy and is caused by inflammation of the lining of the gastrointestinal tract, resulting in ulceration, severe diarrhoea, malnutrition and increased risk of infection. Several commonly administered anti-cancer drugs can damage the digestive tract in this way, including 5-fluorouracil (5-FU), methotrexate, cytarabine, capecitabine, and irinotecan.
Using Epistem’s proprietary stem cell models, CR 3294 has been shown to protect the small intestinal crypts from cytotoxic insult and reduce diarrhoea severity, particularly against frequently used chemotherapy agents such as 5-FU.
Dr Catherine Booth, Managing Director of Epistem’s Contract Research Division commented “Epistem is a world leader in the supply of epithelial research models that measure the efficacy of oncology supportive care agents. CR 3294 protected normal tissue, to reduce the level of mucositis without increasing the risk of tumour growth. Such an increased therapeutic index may allow either improved quality of life for patients or opportunities for chemotherapy dose escalation, and therefore possible increased cure rates”.
Rottapharm announces CR 3294 is under active development and phase I studies are planned for 1st Q 2009.
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.